CHANG NANCY T 4

What Happened

• Nancy T. Chang, a reported 10% owner of Galera Therapeutics (GRTX), had Series B non‑voting convertible preferred shares converted into common stock on April 7, 2026. The filing shows 1,180.611 shares of Series B preferred were converted into 1,180,611 shares of common stock. No cash was paid or received in the conversion (price reported as $0.00 / N/A).

Key Details

• Transaction date: April 7, 2026; Form 4 filed April 9, 2026 (appears timely, within the two‑business‑day window).
• Conversion: 1,180.611 shares of Series B preferred → 1,180,611 common shares.
• Reported price/value: $0.00 or N/A (corporate conversion, not a purchase/sale).
• Shares owned after the transaction: Not specified in the filing.
• Footnote: On Feb 12, 2026 the company amended the Series B designation to allow the board to elect a mandatory conversion at its sole discretion; the April 7 conversion was a partial mandatory conversion and the Series B shares have no expiration (see F1).

Context

• This was a corporate mandatory conversion of preferred into common stock, not an open‑market buy or sale by the insider—so it does not directly signal a buy or sell decision by Chang.
• The conversion ratio used by the company is 1,000 common shares per 1 share of Series B preferred (which explains the 1,180.611 preferred → 1,180,611 common conversion).